Sobi™ publishes its report for the second quarter 2017
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the second quarter 2017. Total revenues amounted to SEK 1,639 M, an increase of 12 per cent. Total revenue growth was 51 per cent excluding one-time items. Product sales amounted to SEK 1,443 M, an increase of 12 per cent (60 per cent adjusted). Elocta® sales were SEK 351 M and Alprolix® sales were SEK 84 M. Business highlights Q2 2017 · Guido Oelkers was appointed CEO and President · Strong quarter on quarter growth · A new Specialty Care business unit was established · Elocta